Immune Landscape of Pancreatic Cancer Development and Drug Resistance

Volume 5
Herausgeber: Farran, Batoul; Nagaraju, Ganji Purnachandra

• Gebundenes Buch

Produktbeschreibung

Immune Landscape of Pancreatic Cancer Development and Drug Resistance explores advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells. With a strong focus on the development of therapeutic methods to improve the survival rates of pancreatic cancer, this book also shows the latest trends in immune targeted approaches for pancreatic cancer treatment. In 12 chapters, the book discusses our current understanding of PC development and its various mutational and immune features and explore some of the new immune-based therapies aimed at targeting pancreatic cancer. This book is a valuable resource for health professionals, scientists and researchers, students, and all those who wish to broaden their knowledge of advances in immunotherapy in pancreatic cancer.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science
• Seitenzahl: 312
• Erscheinungstermin: 14. Juni 2024
• Englisch
• Gewicht: 450g
• ISBN-13: 9780443235238
• ISBN-10: 0443235236
• Artikelnr.: 68541630

Inhaltsangabe

1. Introduction
2. Molecular profiling and mutational landscape of pancreatic cancer
3. Tumor microenvironment and immune components interaction in pancreatic
ductal adenocarcinoma
4. Identification of immune targeted molecules in pancreatic ductal
adenocarcinoma
5. Targeting macrophages for pancreatic cancer therapy
6. Targeting cancer-associated fibroblasts in pancreatic ductal
adenocarcinoma
7. Targeting short-lived immunosuppressive myeloid cells for PDAC therapy
8. Targeting T-regs in PDAC
9. Immune-modulators for PDAC therapy
10. Current clinical trials in PDAC immunotherapy
11. Precision medicine in PDAC immunotherapy
12. Artificial intelligence in pancreatic cancer immunotherapy